BPI-371153
Phase 1Small molecule
BPI-371153 is one of 41 small molecule programs targeting Lymphoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
375 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Cabenuva
GSKPreclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Immune Checkpoint Inhibitor
IImmuneSensor Therapeutics Inc.
Preclinical
Antibody-Drug Conjugate
MMBrace Therapeutics
Preclinical
JY231
SShenzhen Genocury Biotech Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BPI-371153. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- BBetta Pharmaceuticals Co., Ltd.